| Advanced Home Medical Inc | |
| 2212 Fort Campbell Blvd, Hopkinsville, Kentucky 42240 | |
| (270) 886-2544 |
| Name | Advanced Home Medical Inc |
|---|---|
| Organization Name | Advanced Home Medical Inc |
| Location | 2212 Fort Campbell Blvd, Hopkinsville, Kentucky 42240 |
| Type | DME Supplier - Parenteral & Enteral Nutrition |
| Phone | (270) 886-2544 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Cedars-Sinai Medical Center rose for the third year in a row in a national ranking of best places for technology specialists to work, becoming one of the country's top 25 IT employment spots and winning continued recognition for how it values diversity among its employees.
Nevro Corp., a medical device company focused on achieving improved pain relief for patients suffering from debilitating chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for initiation of its SENZA-RCT study, a U.S. prospective, randomized, controlled pivotal clinical trial evaluating the safety and efficacy of Nevro's high-frequency spinal cord stimulation system for the treatment of chronic pain.
Most humans would like to shed their fatty exteriors, but tuberculosis (TB)-causing bacteria rely on theirs for survival. Scientists at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School have now discovered a drug that cripples the TB bug by dissolving its protective fatty coating, a finding that could eventually be used to improve TB treatment in humans. The study has been posted online by Nature Chemical Biology.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
Modifying stomach acid levels may not be enough to treat symptoms in neonates suspected of having gastroesophageal reflux disease. According to a study from Nationwide Children's Hospital, this is the first study to classify reflux and its associated symptoms in neonates based on how and what is refluxed.
› Verified 8 days ago
| NPI Number | 1831287150 |
| Organization Name | ADVANCED HOME MEDICAL INC |
| Type | DME Supplier - Parenteral & Enteral Nutrition |
| Address | 2212 Fort Campbell Blvd, Hopkinsville, KY 42240 |
| Phone Number | 270-886-2544 |
News Archive
Cedars-Sinai Medical Center rose for the third year in a row in a national ranking of best places for technology specialists to work, becoming one of the country's top 25 IT employment spots and winning continued recognition for how it values diversity among its employees.
Nevro Corp., a medical device company focused on achieving improved pain relief for patients suffering from debilitating chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for initiation of its SENZA-RCT study, a U.S. prospective, randomized, controlled pivotal clinical trial evaluating the safety and efficacy of Nevro's high-frequency spinal cord stimulation system for the treatment of chronic pain.
Most humans would like to shed their fatty exteriors, but tuberculosis (TB)-causing bacteria rely on theirs for survival. Scientists at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School have now discovered a drug that cripples the TB bug by dissolving its protective fatty coating, a finding that could eventually be used to improve TB treatment in humans. The study has been posted online by Nature Chemical Biology.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
Modifying stomach acid levels may not be enough to treat symptoms in neonates suspected of having gastroesophageal reflux disease. According to a study from Nationwide Children's Hospital, this is the first study to classify reflux and its associated symptoms in neonates based on how and what is refluxed.
› Verified 8 days ago
News Archive
Cedars-Sinai Medical Center rose for the third year in a row in a national ranking of best places for technology specialists to work, becoming one of the country's top 25 IT employment spots and winning continued recognition for how it values diversity among its employees.
Nevro Corp., a medical device company focused on achieving improved pain relief for patients suffering from debilitating chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for initiation of its SENZA-RCT study, a U.S. prospective, randomized, controlled pivotal clinical trial evaluating the safety and efficacy of Nevro's high-frequency spinal cord stimulation system for the treatment of chronic pain.
Most humans would like to shed their fatty exteriors, but tuberculosis (TB)-causing bacteria rely on theirs for survival. Scientists at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School have now discovered a drug that cripples the TB bug by dissolving its protective fatty coating, a finding that could eventually be used to improve TB treatment in humans. The study has been posted online by Nature Chemical Biology.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
Modifying stomach acid levels may not be enough to treat symptoms in neonates suspected of having gastroesophageal reflux disease. According to a study from Nationwide Children's Hospital, this is the first study to classify reflux and its associated symptoms in neonates based on how and what is refluxed.
› Verified 8 days ago
Advanced Home Medical Inc Type: DME Supplier - Parenteral & Enteral Nutrition Location: 2212 Fort Campbell Blvd, Hopkinsville, Kentucky 42240 Phone: (270) 886-2544 | |
Bastin Optometric Eye Clinic Type: Medicare Supplier Location: 220 W 18th St, Hopkinsville, Kentucky 42240 Phone: (270) 886-2293 | |
Christian County Foot And Ankle Cen Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1610 S Main St, Hopkinsville, Kentucky 42240 Phone: (270) 885-1203 | |
Visionworks Doctors Of Optometry Type: Eyewear Supplier (Equipment, not the service) Location: 4135 Fort Campbell Blvd, Hopkinsville, Kentucky 42240 Phone: (270) 887-5765 | |
Heltsley Eye Care Pllc Type: Medicare Supplier Location: 1620 S Main St, Hopkinsville, Kentucky 42240 Phone: (270) 886-6316 |